One class of antidiabetic drugs, sodium-glucose transporter 2 (SGLT-2) inhibitors, have been shown by four large-scale clinical trials involving T2DM patients that they reduce the risk of hospitalization for heart failure [4, 5, 6, 7]. The gene discussed is SLC5A2; the disease is heart failure.